De LIFE Cooperative bevat bedrijven - van MKB tot startups - van wereldklasse in het Life Sciences en Health Cluster van Noord-Nederland.
This invention involves a unique, inventive, and patented tablet formulation that allows STS to be administered orally in an effective and safe manner, enabling chronic treatment with STS. This has been demonstrated in vitro. The VFF plan represents the next step toward achieving proof of concept for STS as a treatment for CVDs through a clinical study in patients with Raynaud's syndrome.
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is a medical technology company with headquarter in Gothenburg, Sweden, a production site in Lund, Sweden and office in Groningen, The Netherlands and Denver, USA. We are firmly rooted in medical science and our core business is in ex vivo organ preservation. We are focused on developing optimized solutions for organ, tissue and cell preservation and perfusion in connection with transplantation. We have more than 20 years of experience within the transplant industry and are dedicated to providing more effective, clinically proven and innovative products that both increase the availability of acceptable donor organs and improve survival after transplantation.
